The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Elisabeth Moss is leading a rebellion in the sixth and final season "The Handmaid's Tale," which arrives on Hulu April 8.

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Nvidia stock rises after the chip maker makes a number of product announcements at its annual AI GTC conference, Tesla trades ...

So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

The official trailer for The Handmaid's Tale's final season shows June (Elisabeth Moss) returning to Gilead amid a revolution ...

Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...